Kane Biotech Inc.
KNE.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.47M | 553.50K | 121.60K | 109.20K | -1.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.47M | 553.50K | 121.60K | 109.20K | -1.33M |
| Cost of Revenue | 746.70K | 218.50K | 32.50K | 29.00K | -632.80K |
| Gross Profit | 727.40K | 335.20K | 89.20K | 80.30K | -699.10K |
| SG&A Expenses | 2.65M | 2.46M | 1.91M | 1.77M | 680.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.51M | 3.86M | 2.81M | 2.57M | 620.50K |
| Operating Income | -3.03M | -3.31M | -2.69M | -2.46M | -1.95M |
| Income Before Tax | -3.58M | -4.01M | -3.63M | -3.35M | -2.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.58 | -4.01 | -3.63 | -3.35 | -2.93 |
| Earnings from Discontinued Operations | 7.69M | 7.53M | -208.80K | -345.90K | -306.40K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.10M | 3.52M | -3.84M | -3.69M | -3.12M |
| EBIT | -3.03M | -3.31M | -2.69M | -2.46M | -1.95M |
| EBITDA | -2.99M | -3.26M | -2.63M | -2.37M | -1.85M |
| EPS Basic | 0.03 | 0.03 | -0.03 | -0.03 | -0.02 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 |
| EPS Diluted | 0.03 | 0.03 | -0.02 | -0.02 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 |
| Average Basic Shares Outstanding | 525.11M | 518.12M | 510.70M | 503.69M | 497.27M |
| Average Diluted Shares Outstanding | 550.77M | 543.78M | 531.80M | 524.79M | 518.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
